The concordance of the limiting antigen and the Bio-Rad avidity assays in persons from Estonia infected mainly with HIV-1 CRF06_cpx

Background Serological assays to determine HIV incidence have contributed to estimates of HIV incidence, monitoring of HIV spread, and evaluation of prevention strategies. Two frequently used incidence assays are the Sedia HIV-1 LAg-Avidity EIA (LAg) and the Bio-Rad avidity incidence (BRAI) assays with a mean duration of recent infection (MDRI) of 130 and 240 days for subtype B infections, respectively. Little is known about how these assays perform with recombinant HIV-1 strains. We evaluated the concordance of these assays in a population infected mainly with HIV-1 CRF06_cpx. Material/Methods Remnant serum samples (n = 288) collected from confirmed, newly-diagnosed HIV-positive persons from Estonia in 2013 were tested. Demographic and clinical data were extracted from clinical databases. LAg was performed according to the manufacturer’s protocol and BRAI testing was done using a validated protocol. Samples with LAg-pending or BRAI-invalid results were reclassified as recent if they were from persons with viral loads <1000 copies/mL or were reclassified as long-term if presenting with AIDS. Results In total 325 new HIV infections were diagnosed in 2013 in Estonia. Of those 276 persons were tested with both LAg and BRAI. Using assay results only, the recency rate was 44% and 70% by LAg and BRAI, respectively. The majority of samples (92%) recent by LAg were recent by BRAI. Similarly, 89% of samples long-term by BRAI were long-term by LAg. After clinical information was included in the analysis, the recency rate was 44% and 62% for LAg and BRAI, respectively. The majority of samples (86%) recent by LAg were recent by BRAI and 91% of long-term infections by BRAI were long-term by LAg. Conclusions Comparison of LAg and BRAI results in this mostly CRF06_cpx-infected population showed good concordance for incidence classification. Our finding of a higher recency rate with BRAI in this population is likely related to the longer MDRI for this assay.

[1]  E. Kallas,et al.  HIV incidence in the Estonian population in 2013 using the HIV-1 Limiting Antigen Avidity ( LAg ) assay , 2018 .

[2]  K. Curtis,et al.  Short Communication: Persistence of HIV Antibody Avidity in the Presence of Antiretroviral Therapy. , 2016, AIDS research and human retroviruses.

[3]  Angela L Hernandez,et al.  Mean Recency Period for Estimation of HIV-1 Incidence with the BED-Capture EIA and Bio-Rad Avidity in Persons Diagnosed in the United States with Subtype B , 2016, PloS one.

[4]  R. Avi,et al.  Design and structure of the Estonian HIV Cohort Study (E-HIV) , 2015, Infectious diseases.

[5]  C. Morrison,et al.  Comparison of antibody responses to HIV infection in Ugandan women infected with HIV subtypes A and D. , 2015, AIDS research and human retroviruses.

[6]  Reshma Kassanjee,et al.  Recalibration of the Limiting Antigen Avidity EIA to Determine Mean Duration of Recent Infection in Divergent HIV-1 Subtypes , 2015, PloS one.

[7]  Reshma Kassanjee,et al.  Independent assessment of candidate HIV incidence assays on specimens in the CEPHIA repository , 2014, AIDS.

[8]  N. Bannert,et al.  Improved Testing of Recent HIV-1 Infections with the BioRad Avidity Assay Compared to the Limiting Antigen Avidity Assay and BED Capture Enzyme Immunoassay: Evaluation Using Reference Sample Panels from the German Seroconverter Cohort , 2014, PloS one.

[9]  Oliver Laeyendecker,et al.  Incorrect identification of recent HIV infection in adults in the United States using a limiting-antigen avidity assay , 2014, AIDS.

[10]  O. Laeyendecker,et al.  Impact of HIV subtype on performance of the limiting antigen-avidity enzyme immunoassay, the bio-rad avidity assay, and the BED capture immunoassay in Rakai, Uganda. , 2014, AIDS research and human retroviruses.

[11]  KallasEveli,et al.  Transmitted drug resistance is still low in newly diagnosed human immunodeficiency virus type 1 CRF06_cpx-infected patients in Estonia in 2010. , 2014 .

[12]  Anne M Johnson,et al.  Rate of CD4 Decline and HIV-RNA Change Following HIV Seroconversion in Men Who Have Sex With Men: A Comparison Between the Beijing PRIMO and CASCADE Cohorts , 2013, Journal of acquired immune deficiency syndromes.

[13]  Connie Celum,et al.  HIV incidence determination in the United States: a multiassay approach. , 2013, The Journal of infectious diseases.

[14]  John N. Nkengasong,et al.  Detection of Recent HIV-1 Infection Using a New Limiting-Antigen Avidity Assay: Potential for HIV-1 Incidence Estimates and Avidity Maturation Studies , 2012, PloS one.

[15]  T. Spira,et al.  Development and characterization of a bead-based, multiplex assay for estimation of recent HIV type 1 infection. , 2012, AIDS research and human retroviruses.

[16]  J. Parry,et al.  The Effect of Sample Handling on Cross Sectional HIV Incidence Testing Results , 2011, PloS one.

[17]  J. Nkengasong,et al.  Development of two avidity-based assays to detect recent HIV type 1 seroconversion using a multisubtype gp41 recombinant protein. , 2010, AIDS research and human retroviruses.

[18]  R. Avi,et al.  Absence of genotypic drug resistance and presence of several naturally occurring polymorphisms of human immunodeficiency virus‐1 CRF06_cpx in treatment‐naive patients in Estonia , 2009, Journal of medical virology.

[19]  J. Parry,et al.  Human Immunodeficiency Virus (HIV) Antibody Avidity Testing To Identify Recent Infection in Newly Diagnosed HIV Type 1 (HIV-1)-Seropositive Persons Infected with Diverse HIV-1 Subtypes , 2006, Journal of Clinical Microbiology.

[20]  R. Villems,et al.  Predominance of a Rare Type of HIV-1 in Estonia , 2005, Journal of acquired immune deficiency syndromes.

[21]  G. Satten,et al.  Performance characteristics of a new less sensitive HIV-1 enzyme immunoassay for use in estimating HIV seroincidence. , 2003, Journal of acquired immune deficiency syndromes.

[22]  R. Janssen,et al.  Development of a new less-sensitive enzyme immunoassay for detection of early HIV-1 infection. , 2003, Journal of acquired immune deficiency syndromes.

[23]  R. Byers,et al.  Quantitative detection of increasing HIV type 1 antibodies after seroconversion: a simple assay for detecting recent HIV infection and estimating incidence. , 2002, AIDS research and human retroviruses.